Antimicrobial Drug Discovery from Coevolved Symbiotic Communities

大型制药公司的抗菌药物创新已经放缓到爬行，而耐药性的流行病 感染激增，威胁公众健康。威斯康星州抗菌药物的总体目标 发现和发展中心是制定治疗对策，以解决抗菌 抵抗危机根据我们的初步数据，我们假设， 使用互补和综合尖端方法的共生环境将提供新的 抗微生物药物发现的范例。该中心提出了创新的概念和技术 克服传统抗微生物药物发现平台中确定的关键瓶颈的进展， 为耐药性流行病提供治疗对策。

Antimicrobial innovation by Big Pharma has slowed to a crawl while an epidemic of antimicrobial-resistant infections surges, threatening the public health. The overarching goal of the Wisconsin Antimicrobial Drug Discovery and Development Center is to develop therapeutic countermeasures to tackle the antimicrobial resistance crisis. Based upon our preliminary data, we hypothesize that natural product exploration of symbiotic environments using complementary and integrated cutting-edge approaches will provide a new paradigm for antimicrobial drug discovery. The Center proposes innovative conceptual and technical advances to overcome critical bottlenecks identified in traditional antimicrobial drug discovery platforms to deliver therapeutic countermeasures for the drug-resistance epidemic.